timothy sykes logo

Stock News

Can DexCom’s Stock Keep Rising?

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 6/24/2025, 2:33 pm ET 6/24/2025, 2:33 pm ET | 5 min 5 min read
Can DexCom’s Stock Keep Rising? Thumbnail

DexCom Inc. stocks have been trading up by 8.2 percent amid investor excitement over strong quarterly earnings and strategic partnerships.

  • Analysts at Truist have started covering DexCom with a “Buy” rating and a price target of $102, aligning with a strong positive consensus among other market experts. The average target price of $100.36 mirrors broad bullish sentiment.

Candlestick Chart

Live Update At 14:32:47 EST: On Tuesday, June 24, 2025 DexCom Inc. stock [NASDAQ: DXCM] is trending up by 8.2%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In the fast-paced world of trading, there are essential strategies that can significantly impact one’s success. It is crucial for traders to adhere to certain principles to maximize profits and minimize risks. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” These words of wisdom remind traders of the importance of exiting losing trades promptly to prevent further losses, allowing winning trades to continue generating profits, and avoiding excessive trading that may lead to costly mistakes. Such disciplined approaches can help traders achieve consistent growth and avoid emotional pitfalls in the market.

DexCom has been making noticeable gains recently, not just in the stock market but also within the healthcare industry. Their earnings report displays a well-rounded growth trajectory. For Q1 of 2025, revenue reached over $4 billion, representing a significant surge compared to previous periods. The earnings suggest an adept management team, capable of capitalizing on market opportunities.

Analyzing key ratios provides insight: a high price-to-earnings (PE) ratio over 60 suggests high investor expectations. Their gross margin stands at 59.4%, illustrating strong control over production costs relative to revenue. Moreover, financial strength ratios like total debt to equity, pegged at 1.11, show balanced financial leverage.

Recent movements in their stock, particularly on Jun 24, 2025, where prices rallied from approximately $80 to over $86, reflect investor enthusiasm. These price adjustments, verified by both daily and intraday trends, point towards a potentially justified uptrend for the company.

Why the Surge?

The belief in DexCom’s CGM technology is a powerful catalyst. Reports indicating its vital role in diabetes management give investors reasons to be hopeful. They foresee expanding market capture as the tech complements other diabetes medications, thus hinting at increased future revenue streams.

More Breaking News

In the backdrop of these bullish expectations, financial analysts like those at Truist and Goldman Sachs have initiated “Buy” ratings. They project encouraging price targets, indicating belief in renowned growth potential. While DexCom’s shares are flying high, analysts wonder: “Is it time to buy?”

Speculated Performance

With strong market sentiments backing DexCom, the market is poised for continued positive reactions if the company’s future announcements align with current expectations. DexCom’s commitment to diabetes technology puts it at the frontier of health innovation. As healthcare professionals embrace technology more extensively, DexCom appears well-positioned for this competitive edge.

Investor sentiment might be carefully gauged given their past performance, where they easily maneuvered economic peaks and valleys. DexCom’s strategic investments in proprietary technology are a promising venture. By consistently innovating, DexCom taps into sustained growth opportunities.

As investors digest this optimistic outlook, caution arises. DexCom’s high valuation metrics, such as the PE ratio and price-to-sales ratio, could signal overvaluation risks. Yet, the enticing financial indicators suggest there remains significant upside potential if market conditions and expectations are met.

DexCom’s Future: Opportunity or Risk?

This latest surge in DexCom’s stock price could very well present an opportunity for both growth traders and market participants. Caution is necessary, yet the strategic deployments seen in DexCom could pave the way for reliable profitability. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” DexCom is consistently revisiting and enhancing its market strategies. The intertwining of technology with traditional medicine represents a defining trend. Should market dynamics maintain current trajectories, those trading in DexCom may similarly witness favorable tides, balancing opportunity against the potential risks.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”